Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/26/2026

1. MU
2. QCOM
3. SPY
4. JPM
5. ICLR
6. USO
7. LAES
8. FUL

Go back to Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress

Fate Therapeutics (FATE) Misses Q2 EPS by 8c

August 5, 2020 5:35 PM EDT

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.35), $0.08 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $5.5 million versus the consensus estimate of $13.23 million.

Early clinical data from our FT596 program are very encouraging, as we observed a partial response in a heavily-pretreated patient with... More